Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orforglipron in Hypertension and Obesity or Overweight
NCT06952530Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2025
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 3 trial of orforglipron in hypertension (HTN), sponsored by Eli Lilly and Company. Started Apr 2025; status: active, not recruiting.
02
Drugs
orforglipron
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT06952530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06952530.